Blockade of SARS-CoV-2 infection in-vitro by highly potent PI3K-α/mTOR/BRD4 inhibitor
A. Acharya, K. Pandey, M. Thurman, K. B. Challagundla, K. R. Vann, T. G. Kutateladze, G. A. Morales, D. L. Durden, S. N. Byrareddy
The paper demonstrates that SF2523, a PI3K-α/mTOR/BRD4 inhibitor, effectively blocks SARS-CoV-2 replication in vitro with an IC50 of 1.5 μM and shows synergy with remdesivir.
bioRxiv · Mar 2, 2021 · PreprintPharmacology & Toxicology